Subject:
- Active Substance: Secukinumab
- Name; Cosentyx®
- Therapeutic area: Enthesitis-associated arthritis
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 15.07.2022
- Final decision by G-BA: 05.01.2023
Final decision:
- No additional benefit proved